atlantic h 24
TRANSCRIPT
The ATLANTIC-HThe ATLANTIC-H2424 Analysis AnalysisEffect of Pre-Hospital Ticagrelor During
the First 24 h After Primary Percutaneous Coronary Intervention in
Patients With STEMI.
J A C C : CARDIOVASCULAR INTERVENTIONS
VOL. 9, NO. 7, 2016
Dr.Vinit KumarMCH, Trivandrum
The aim of this landmark exploratory analysis, ATLANTIC-H, was to evaluate the effects of pre-hospital ticagrelor during the first 24 h after primary PCI in the ATLANTIC Study.
Indications and guideline Indications and guideline recommendationsrecommendations
• ESC STEMI guidelines recommend:[Steg 2012]
– An ADP-receptor blocker in addition to ASA. Options are:
• Prasugrel in clopidogrel-naïve patients, if no history of prior stroke/TIA, age <75 years (Class I, LOE B)
• Ticagrelor (Class I, LOE B)
• Clopidogrel, preferably when prasugrel or ticagrelor are either not available or contraindicated (Class I, LOE C)
• ESC/EACTS myocardial revascularization guidelines recommend:[Kolh 2014]
– An ADP-receptor blocker in addition to ASA for STEMI primary PCI. Options are:
• Prasugrel if no history of prior stroke/TIA, age <75 years (Class I, LOE B)
• Ticagrelor (Class I, LOE B)
• Clopidogrel, only when prasugrel or ticagrelor are not available or contraindicated (Class I, LOE B)
ESC/EACTS treatment guideline ESC/EACTS treatment guideline recommendations for patients with STEMIrecommendations for patients with STEMI
Steg G et al. Eur Heart J 2012;33:2569–2619; Kolh P et al. Eur Heart J August 29 2014; DOI:10.1093/eurheart/ehu278 [Epub ahead of print]
• ACCF/AHA guidelines recommend:[O’Gara 2013]
– A loading dose of a P2Y12 inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include:
• Clopidogrel 600 mg (Class I; LOE B)
• Prasugrel 60 mg (Class I; LOE B)
• Ticagrelor 180 mg (Class I; LOE B)
ACCF/AHA treatment guideline ACCF/AHA treatment guideline recommendations for patients with recommendations for patients with
STEMISTEMI
O’Gara PT et al. Circulation 2013;127:e362–425
• While pre-hospital initiation of oral antiplatelet treatment is not recommended specifically, the 2012 ESC STE-ACS guidelines acknowledge that it is common practice in Europe[Steg 2012]
– Early administration may be preferable to achieve early efficacy
• The new ESC/EACTS guidelines recommend initiation of DAPT at first medical contact* in STEMI primary PCI[Kolh 2014]
Treatment guidelines: Treatment guidelines: Timing of antiplatelet therapy in STEMITiming of antiplatelet therapy in STEMI
*The point at which the patient is either initially assessed (12-lead ECG) by a paramedic or physician or other medical personnel in the pre-hospital setting, or the patient arrives at the hospital emergency department, and therefore often in the outpatient setting
Steg G et al. Eur Heart J 2012;33:2569–2619.Kolh P et al. Eur Heart J August 29 2014; DOI:10.1093/eurheart/ehu278 [Epub ahead of print]
ATLANTICATLANTIC
AAdministration of dministration of TTicagrelor in the cath icagrelor in the cath LLab or in ab or in the the AAmbulance for mbulance for NNew Sew STT elevation myocardial elevation myocardial
IInfarction to open the nfarction to open the CCoronary arteryoronary artery
A 30-day study to evaluate the efficacy and safetyof pre-hospital versus in-hospital initiation of ticagrelor therapy in STEMI patients planned for PCI
• To evaluate whether earlier, in-ambulance administration of ticagrelor could safely improve coronary reperfusion in patients with acute ST-elevation myocardial infarction (STEMI) transferred for primary percutaneous coronary intervention (PCI)
ATLANTIC: AimATLANTIC: Aim
Montalescot G et al. Am Heart J 2013;165:515–522
• Guidelines’ recommendation to administer antiplatelet therapy as early as possible before angiography is not based on randomized controlled trial (RCT) results
• No clear evidence for benefit of clopidogrel administration pre-hospital versus in-hospital in patients undergoing primary PCI
– No difference in coronary patency or bleeding[Zeymer 2012]
– Ischaemic events may be reduced without excess bleeding, but effectiveness may be limited by slow onset of action and variability of response[Bellemain-Appaix 2012]
Pre-hospital administration of Pre-hospital administration of antiplatelet therapyantiplatelet therapy
; Zeymer U et al. Clin Res Cardiol 2012;101:305–312; Bellemain-Appaix A et al. JAMA 2012;308:2507–2516
• Ticagrelor significantly reduced the risk of CV death, MI or stroke in ACS patients compared with clopidogrel in the PLATO study[Wallentin 2009]
– Results in a subgroup analysis of patients with STE-ACS planned to undergo primary PCI were consistent with the overall study[Steg 2010]
• No specific studies have been conducted to evaluate the potential benefit of treatment with ticagrelor prior to hospitalisation
• Therefore, the primary objective of the ATLANTIC study is to assess the optimal timing of ticagrelor initiation in STEMI patients planned for primary PCI
Study rationaleStudy rationale
Steg PG et al. Circulation 2010;122:2131–2141;Wallentin L et al. N Engl J Med 2009;361:1045–1057
ATLANTICATLANTICStudy design
ATLANTIC study population and designATLANTIC study population and design
Ticagrelor 180 mg loading dose
Placeboloading dosePre-hospital
Placeboloading dose
Ticagrelor 180 mg loading doseIn-hospital
Randomized, double-blind
Ticagrelor 90 mg/bid 30 days
Primary objective
OR
STE-ACS planned for PCIN=1770 (n=1862*)
Written informed consent in mobile care unitSymptoms of acute MI or more than 30 min but less than 6 h
New persistent ST-segment elevation ≥1 mm in two or more contiguous ECG leads
≥70% ST-segment elevation resolution pre-PCI
TIMI flow grade 3 of MI culprit vessel at initial angiography
*Consented and randomized
• Aged ≥18 years• Diagnosed with STEMI (new, persistent ST-segment elevation
≥1 mm in≥2 continuous ECG leads)
• Planned to undergo primary PCI• Symptoms of acute MI >30 minutes but <6 hours in duration• Initially treated by the emergency medical service (ambulance
personnel)
Diagnosis and inclusion into the study are made solely by the ambulance personnel
ATLANTIC: Key inclusion criteriaATLANTIC: Key inclusion criteria
Expected time from qualifying ECG to first PCI balloon inflation in hospital of >120 minutes
Received a loading dose for the index event, or receiving maintenance treatment with ticagrelor, clopidogrel or prasugrel
Concomitant medication that may increase the risk of bleeding administered 24 hours before randomization or strong cytochrome P450 3A inhibitors.
ATLANTIC: Key exclusion criteriaATLANTIC: Key exclusion criteria
16
• Planned surgery during the study period
• Known clinically important thrombocytopenia or anaemia
• Requirement for dialysis
• Any of the following conditions in the absence of a functioning implanted pacemaker: Known sick sinus syndrome, second- or third-degree AV block, or documented syncope of suspected bradycardic origin
• Previous randomization in ATLANTIC or participation in another clinical study with an investigational product or a device study during the previous 30 days and during the study
• To assess the efficacy of pre-hospital administration of ticagrelor compared to an in-hospital administration by comparing percentage of patients not achieving the co-primary endpoints:
ATLANTIC: Primary objectiveATLANTIC: Primary objective
• Percentage of patients not achieving ≥70% ST-segment elevation resolution at pre-PCI
• Percentage of patients not reaching TIMI flow grade 3 in the infarct-related artery at initial (pre-PCI) angiography
ATLANTIC: Co-primary ATLANTIC: Co-primary endpointsendpoints
Complete ST-segment elevation resolution at 60 min post-PCI
TIMI flow grade 3 at end of procedure Definite stent thrombosis alone at 30 days Thrombotic bailout with GPIIb/IIIa inhibitors
ATLANTIC: Pre-specified secondary ATLANTIC: Pre-specified secondary endpointsendpoints
• To assess the safety of pre-hospital versus in-hospital initiation of ticagrelor therapy
ATLANTIC: Safety objectivesATLANTIC: Safety objectives
Bleeding events–Major life-threatening or other minor or major
bleeding events• PLATelet inhibition and patient Outcomes (PLATO)
bleeding definition• Within first 48 h and during first 30 days of treatment
• Excluding CABG-related bleeding events
ATLANTIC study flow chartATLANTIC study flow chart
Administration of in-ambulance GPIIb/IIIa inhibitors discouraged; post-angiogram in-lab use of GPIIb/IIIa inhibitors only if identified as treatment of choice or bail-out option during PCI. Continuation of ticagrelor for 12 months recommended
Secondary endpoints
PCI
R
Ticagrelor 180 mg
Placebo
Placebo
Ticagrelor 180 mg
LD1
ECG 1 Diagnosis
H12 post LD2
Ticagrelor 90 mg BID
ECG 2 Pre-PCI ECG 3 60’ Post-PCI-
LD2
Double-blind period 30-day active treatment period
7 days’ follow-up
Pre-hospital settings Cath lab
STEMI planned for PCIn=1870
Primary endpoints
Secondary endpoints
Cat
h la
b D
OO
R
Shea
th in
sert
ion
Ang
iogr
aphy
Firs
t mai
nten
ance
dos
e
• Efficacy analysis based on the modified ITT population analysis set
– Analysis included all patients who received at least one dose of study drug
– Selected because randomization and administration of the first dose of study drug occur simultaneously, in the ambulance
– Each co-primary endpoint analyzed separately using the χ2 test
• Safety population analysis included all randomized patients who received at least one dose of study drug
– Safety endpoints analyzed using descriptive methods
ATLANTIC: AnalysisATLANTIC: Analysis
Baseline patient characteristicsBaseline patient characteristics
Values are n (%)
Ticagrelor pre-hospital
(n=909)
Ticagrelor in-hospital
(n=953) Coronary angiography 890 (97.7) 937 (98.3)
Arterial access (percentage of those undergoing coronary angiography)FemoralRadial
280/890 (31.5)604/890 (67.9)
309/937 (33.0)625/937 (66.7)
Thrombo-aspiration 471 (51.8) 470 (49.3)
PCI With stent
Drug-eluting stents Bare metal stents
Without stent
800 (88.0)760 (83.6)467 (51.4)305 (33.6)40 ( 4.4)
830 (87.1) 776 (81.4)479 (50.3)312 (32.7)54 ( 5.7)
CABG No PCI or CABG
10 (1.1)99 (10.9)
15 (1.6)108 (11.3)
Procedures for index eventProcedures for index event
Montalescot G et al. N Engl J Med September 1, 2014 [Epub ahead of print; DOI: 10.1056/NEJMoa1407024]
Culprit vessel (percentage of those undergoingCulprit vessel (percentage of those undergoingcoronary angiography)coronary angiography)
Reported for the culprit vessel only
Ticagrelor pre-hospital
Ticagrelor in-hospital
Median times to pre- and in-Median times to pre- and in-hospital stepshospital steps
159 min
28 min
31 min73 min 14 min
90 min 63 min
Onset ofsymptoms
ECG Pre-hospital
Randomization
LD1 LD2ECG
Pre-PCI Angiography PCI
ATLANTICATLANTICStudy results
Co-primary and secondary surrogate Co-primary and secondary surrogate endpointsendpoints
Absence of ST-segment elevation ≥70%
• Pre-PCI†
– Pre-hospital n=774– In-hospital n=824
• Post-PCI‡
– Pre-hospital n=713– In-hospital n=743
Pre-PCI Post-PCI
P=NS
P=NS
Pre-hospitalIn-hospital
• Pre-PCI†
– Pre-hospital n=824– In-hospital n=856
• Post-PCI‡
– Pre-hospital n=760– In-hospital n=784
Co-primary and secondary surrogate Co-primary and secondary surrogate endpointsendpoints
Absence of TIMI flow grade 3 in infarct-related artery
P=NS
P=NS
Pre-hospitalIn-hospital
Post-PCI
Absence of ST-segment elevation ≥70% Absence of ST-segment elevation ≥70% AND/ORAND/OR
Absence of TIMI flow grade 3 in infarct-related arteryAbsence of TIMI flow grade 3 in infarct-related artery
• Pre-PCI†
– Pre-hospital n=744– In-hospital n=777
• Post-PCI‡
– Pre-hospital n=763– In-hospital n=775
P=NS
P=NS
Pre-hospitalIn-hospital
Pre-PCI Post-PCI
• Pre-PCI† – Pre-hospital n=719– In-hospital n=751
• Post-PCI‡
– Pre-hospital n=684– In-hospital n=703
P=NS
P=NS
Pre-hospitalIn-hospital
Pre-PCI Post-PCI
Absence of ST-segment elevation ≥70% Absence of ST-segment elevation ≥70% ANDAND
Absence of TIMI flow grade 3 in infarct-related arteryAbsence of TIMI flow grade 3 in infarct-related artery
n (%)
Ticagrelor pre-hosp(n=906)
Ticagrelor in-hosp(n=952)
Odds ratio(95% CI) P value
Difference(95% CI)
Composite of death/MI/stroke/ urgent revascularization/definite acute stent thrombosis
41 (4.5) 42 (4.4) 1.03(0.66, 1.60) 0.9056 0.001
(–0.018, 0.020)
Composite of death/MI/urgent revascularization 39 (4.3) 34 (3.6) 1.22
(0.76, 1.94) 0.4168 0.007 (–0.010, 0.025)
Clinical endpoints at 30 daysClinical endpoints at 30 daysComposites (mITT)
n (%)
Ticagrelor pre-hosp(n=906)
Ticagrelor
in-hosp(n=952)
Odds ratio(95% CI) P value
Difference(95% CI)
Definite stent thrombosis (at 30 days)
Early stent thrombosis (within 24 h of index PCI)
2 (0.2)
0
11 (1.2)
8 (0.8)
0.19
(0.04, 0.86)
0.02†
0.008†
–0.009 (–0.017, –0.002)
–0.008 (–0.017, –0.003)§
Acute stent thrombosis (definite or probable at 30 days)
21 (2.3) 20 (2.1) 1.11 (0.60, 2.05)
0.75‡ 0.02 (–0.011, 0.016)
Clinical endpoints at 30 daysClinical endpoints at 30 days
Events occurring up to the date of last study visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurredmITT analysis: Each event is counted once in each row. A single event may be counted in more than one row. Odds ratios for pre-hospi tal group versus in hospi tal group, two-sided 95% CIs and P values were calculated from a logistic regression model , wi th treatment as the only explanatory variable†Fisher ’s exact test‡Probable stent thrombosis was defined as any death occurring in a stented patient within 30 days§Exact confidence intervalDifference in binomial proportions calculated for pre-hospital – in-hospital ticagrelor
Stent thrombosis (mITT)
2
1
Definite acute stent thrombosis up to 30 Definite acute stent thrombosis up to 30 daysdays
Kaplan–Meier curves
Ticagrelor pre-hospital 2/906 (0.2%) vs ticagrelor in-hospital 11/952 (1.2%) OR 0.19 (95% CI 0.04, 0.86), P=0.02
0 6 12 18 24 302 8 14 20 264 10 16 22 28
Even
t rat
e (K
M %
)
0
Time (days)
Ticagrelor pre-hospitalTicagrelor in-hospital
24 hP=0.008
30 daysP=0.02
n (%)
Ticagrelor pre-hosp(n=906)
Ticagrelor in-hosp(n=952)
Odds ratio(95% CI) P value
Difference(95% CI)
Death (all-cause)* 30 (3.3) 19 (2.0) 1.68 (0.94, 3.01)
0.08† 0.013 (–0.001, 0.028)
MI 7 (0.8) 10 (1.1) 0.73 (0.28, 1.94)
0.53† –0.003 (–0.011, 0.006)
Stroke 4 (0.4) 2 (0.2) 2.11 (0.39, 11.53)
0.39† 0.002 (–0.004, 0.009)‡
TIA 0 1 (0.1) Not estimable –0.001 (–0.006, 0.003)‡
Urgent coronary revascularization 5 (0.6) 8 (0.8) 0.66 (0.21, 2.01)
0.46† –0.003 (–0.010, 0.005)
Bail-out with GP IIb/IIIa inhibitors 78 (8.6) 100 (10.5) 0.80 (0.59, 1.10)
0.17 –0.019 (–0.046, 0.008)
Clinical endpoints at 30 daysClinical endpoints at 30 days
*
Almost all causes of death were related to cardiogenic shock, cardiac arrest, or cardiac rupture rather than bleeding or ischaemic events. Patient records have been specifically examined and no treatment related effect can be discerned†Fisher’s exact test‡Probable stent thrombosis was defined as any death occurring in a stented patient within 30 daysEvents occurring up to the date of last study visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurredmITT analysis: Each event is counted once in each row. A single event may be counted in more than one row. Odds ratios for pre-hospital group versus in hospital group, two-sided 95% CIs and P values were calculated from a logistic regression model, with treatment as the only explanatory variableDifference in binomial proportions calculated for pre-hospital – in-hospital ticagrelor
Other CV and thrombotic bail-out (mITT)
Non-CABG-related bleeding eventsNon-CABG-related bleeding events
Pre-hospital n=908; in-hospital n=950Events occurring up the date of the last visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurred. Patients may be counted in more than one bleeding event categoryP values were calculated from Chi-square test
PLATO definitions (safety population)
Within 48 h of first dose After 48 h up to 30 d
Major Minor Composite of major
and minor
Major Minor Composite of major
and minor
P=NS
P=NS
P=NS
P=NS
P=NS
P=NS
Pre-hospitalIn-hospital
Non-CABG-related bleeding eventsNon-CABG-related bleeding events
Pre-hospital n=908; in-hospital n=950Events occurring up the date of the last visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurred. Patients may be counted in more than one bleeding event categoryP values were calculated from Chi-square test. Statistical tests were not pre-specifiedSTEEPLE, Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation
TIMI, STEEPLE definitions (safety population)
Major Minor Minimal
TIMI
P=NS
P=NS
P=NS
Major Minor Minimal
STEEPLE
P=NS
P=NS
P=NS
Pre-hospitalIn-hospital
Non-CABG-related bleeding eventsNon-CABG-related bleeding events
Pre-hospital n=908; in-hospital n=950Events occurring up the date of the last visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurred. Patients may be counted in more than one bleeding event categoryP values were calculated from Chi-square test. Statistical tests were not pre-specifiedGUSTO, Global Use of Strategies to Open Occluded Arteries; ISTH, International Society on Thrombosis & Haemostasis
GUSTO and ISTH definitions (safety population)
Severe or life-threatening
Moderate Mild
GUSTO
Major Clinically relevant non-major
Unknown
ISTH
P=NS P=NS
P=NSP=NS
P=NS
Pre-hospitalIn-hospital
Non-CABG-related bleeding eventsNon-CABG-related bleeding events
Pre-hospital n=908; in-hospital n=950Events occurring up the date of the last visit (to a maximum of 32 days) are included in the table. Patients could be on study treatment or not when the event occurred. Patients may be counted in more than one bleeding event categoryP values were calculated from Chi-square test. Statistical tests were not pre-specified BARC, Bleeding Academic Research Consortium
BARC definitions (safety population)
Type 0 Type 1 Type 2 Type 3a Type 3b Type 3c Type 4 Type 5a Type 5b
Unknown
BARC
Pre-hospitalIn-hospital
ATLANTICATLANTICSummary and conclusions
• ATLANTIC was an international, multicentre, randomized, double-blind study in 1862 patients with ongoing STEMI of less than 6 h, comparing pre-hospital (in-ambulance) versus in-hospital (in-catheterization laboratory) treatment with ticagrelor or placebo
• The two co-primary endpoints did not differ between the pre- and in-hospital ticagrelor groups
• Post-PCI ST-segment elevation resolution ≥70% was reported in 57.5% and 52.5% of patients (P=0.055), respectively
ATLANTIC: summary of resultsATLANTIC: summary of results
44
• MACE were not different between the two groups– Mortality was low and there was a numerical imbalance
of deaths in the pre-hospital group vs the in-hospital group (3.3% vs 2.0%). Patient records have been specifically examined and no treatment related effect can be discerned
– Definite stent thrombosis occurred less frequently in the pre-hospital arm (0% vs 0.8% in the first 24 hours; 0.2% vs 1.2% at 30 days)
• Major bleeding event rates at 48 h and 30 days were low and identical between the two study groups whichever bleeding definitions were used
Primary aim of the main ATLANTIC study was to evaluate coronary reperfusion on admission to the catheterization laboratory with pre- versus in-hospital ticagrelor, with 30- day follow-up for clinical outcomes,
The landmark ATLANTIC-H analysis focused on endpoints during the first 24 h after PCI in patients who underwent PCI.Landmark analysis began at the start of the PCI procedure and continued up to 24 h later
Efficacy analyses were performed on the modified intent-to-treat population, defined as all randomized patients who received at least 1 dose of the study drug.
The safety analysis included all patients who received at least 1 dose of the study drug.
MethodsMethodsCoronary reperfusion endpoints were the following: ST-segment elevation resolution measured as the percentage of patients achieving <70% ST-segment elevation resolution 1 h after PCI and the average degree of St segment elevation resolution 1 h after PCI (median %);TIMI flow measured as the percentage of patients reaching TIMI flow grade 3 in the infarct related artery at the end of PCI
Clinical endpoints evaluated over the first 24 h after PCI included the composite endpoint- evaluating death and myocardial ischemic events of myocardial infarction (MI), definite stent thrombosis, urgent revascularization, or per-procedure bail-out use of a glycoprotein IIb/IIIa inhibitor (defined as any use of glycoprotein IIb/IIIa inhibitor after the start of PCI and not including any that were given after coronary angiography but before PCI)
ResultsResultsPLATELET FUNCTION SUBSTUDY-(n - 37) recruited at 5 centersPRU levels showing the biological effect of ticagrelor did not become apparent until 1 h after PCI
PRIVATE-ATLANTICPRIVATE-ATLANTICPLATELET FUNCTION SUBSTUDY-(n - 37) recruited at 5 centers
How PRIVATE-ATLANTIC How PRIVATE-ATLANTIC supports ATLANTICsupports ATLANTIC
Ischaemic events
CV mortalityBleeding
TIMI flowST-segment resolution
VASPVerifyNow PRIVATE-
ATLANTIC
ATLANTIC
Primary objective• To assess platelet inhibition of pre-hospital versus
in-hospital initiation of ticagrelor therapy, when catheterization starts (pre PCI) (T1), measured by VASP-PRI
Secondary objectives• To assess platelet inhibition of pre-hospital versus in-hospital
initiation of ticagrelor therapy, post-PCI (end of procedure) (T2), 1 h post-PCI (T3), 6 h post-PCI (T4), and 12 h post-PCI before the first maintenance dose (T5), measured by VASP-PRI and Verify Now
ObjectivesObjectives
Ticagrelor pre-hospital versus in-Ticagrelor pre-hospital versus in-hospital hospital
for VASP-PRIfor VASP-PRIPre hospital (pre-treatment) In hospital (cath lab) P=NS P=NS P=NS
P=NS
P=NS
T1 (Pre PCI) + 67’
T2 (End of PCI) + 1h44’
T3 (H1 Post PCI) + 2h59’
T4 (H6 Post PCI) + 8h59’
T5 (Before MD)+ 14h25’
LD1 LD2
0
20
40
60
80
100
Pre-PCI TIMI Flow and ST resolution
Post-PCI ST resolution
Primary objective
VASP
-PR
I (%
)
PER-PROCEDURE THROMBOTIC PER-PROCEDURE THROMBOTIC GLYCOPROTEINGLYCOPROTEIN
IIb/IIIa INHIBITOR BAIL-OUT USEIIb/IIIa INHIBITOR BAIL-OUT USE
Bail-out use of glycoprotein IIb/IIIa inhibitors was numerically lower with pre-hospital versus in-hospital administration of ticagrelor (9.4% vs. 12.0%).
POST-PROCEDURE CORONARY POST-PROCEDURE CORONARY REPERFUSIONREPERFUSION
No significant differences between the pre- and in-hospital ticagrelor groups in terms of either post-PCI TIMI flow grade 3 or >70% ST-segment elevation resolution at 1 h.
The degree of ST-segment elevation resolution after PCI was significantly different between the 2 groups
Among the characteristics of the 11 patients who died during the 24 h after PCI, the mean age was much older than that of the 1,618 patients who survived the first 24 h (p < 0.0001), andhigher proportions of female and diabetic patients died than Survived (p - 0.025 and p - 0.022, respectively)A numerically greater percentage of patients who died had an anterior MI compared with those who survived. Significantly more patients who died had a TIMI risk score >6 compared with survivors (p < 0.0001),
average TIMI score of 5.2 versus 2.0, respectively (p < 0.0001), and
Killip class >1 was reported in 27.3% versus 4.6% (p - 0.001).
Patients who died were more likely to have had femoral sheath insertion than those who did not (p ¼ 0.023) and were less likely to have received a drug-eluting stent (p ¼ 0.038
The present exploratory analysis is consistent with the main findings of the ATLANTIC study and demonstrates further that the first hours after PCI are a vulnerable period, with potential benefits of pre-hospital use of ticagrelor in STEMI patients undergoing primary PCI.
It has also been reported that administration of crushed ticagrelor tablets may allow earlier platelet inhibition compared with whole tablets.
STUDY LIMITATIONSSTUDY LIMITATIONS
The exploratory nature of this posthoc Study
A limitation related to the sample size, particularly for the platelet function substudy as numbers were small and
the differences were not statistically significant for all the endpoints.
WHAT IS KNOWNWHAT IS KNOWNThe ATLANTIC study was designed to evaluate the potential effects of pre-hospital oral antiplatelet therapy with ticagrelor
The results showed no significant difference in pre-PCI coronary reperfusion with a pre- versus in-hospital ticagrelor loading dose.
The transfer time was very short and the antiplatelet effects of ticagrelor may not have manifested until after this time
WHAT IS NEWWHAT IS NEWThe ATLANTIC-H24 exploratory analysis confirmed that maximal inhibition of platelet reactivity with pre-hospital ticagrelor occur 1 h after PCI
Significant differences in favor of the pre-hospital ticagrelor group in terms of the degree of ST-segment elevation resolution and the composite ischemic endpoint
WHAT IS NEXTWHAT IS NEXTObservation of the effects of pre- versus in-hospital oral antiplatelet therapy in STEMI patients in a realworld context, where transfer delays are likely longer than we observed, would provide further evidence.
THANKS